Neuroimaging and APOE genotype: A systematic qualitative review

Dementia and Geriatric Cognitive Disorders

Volumn 24, Issue 5, 2007, Pages 348-362

  Cherbuin, Nicolas ^a   Leach, Liana S ^a   Christensen, Helen ^a   Anstey, Kaarin J ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; Apolipoprotein E; Braak stages; Cognitive aging; Magnetic resonance imaging

Indexed keywords

APOLIPOPROTEIN E; GLUCOSE;

ALLELE; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN FUNCTION; BRAIN SIZE; BRAIN VENTRICLE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE COURSE; DOPPLER ECHOGRAPHY; ENTORHINAL CORTEX; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GLUCOSE METABOLISM; HIPPOCAMPUS; HOMOZYGOSITY; HUMAN; MEMORY DISORDER; MORPHOMETRICS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITATIVE RESEARCH; REFERENCE DATABASE; REVIEW; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; WHITE MATTER;

AGE FACTORS; APOLIPOPROTEINS E; ATROPHY; BRAIN; BRAIN DISEASES; BRAIN MAPPING; CEREBROVASCULAR CIRCULATION; HUMANS;

EID: 35648957287     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109150     Document Type: Review

References (93)

1. Blacker D, et al: ApoE-4 and age at onset of Alzheimer's disease: The NIMH genetics initiative. Neurology 1997;48:139-147.
2. Gong J-S, et al: Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem 2002;277:29919-29926.
3. Martins CA, et al: APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005;65:1888-1893.
4. Fazekas F, et al: The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis. J Neurol Sci 2006;245:35-39.
5. Horsburgh K, et al: The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging 2000;21:245-255.
6. Smith JD: Apolipoproteins and aging: emerging mechanisms. Ageing Res Rev 2002;1:345-365.
7. Savitz J, et al: Apolipoprotein E variants and cognition in healthy individuals: a critical opinion. Brain Res Rev 2006;51:125-135.
8. Jorm AF, et al: APOE genotype and cognitive functioning in a large age-stratified population sample. Neuropsychology 2007;21:1-8.
9. Teter B: Life-span influences of apoE4 on CNS function. Neurobiol Aging 2006;28:693-703.
10. Braak H, et al: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berl) 2006;112:389-404.
11. Braak H, et al: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
12. Ohm TG, et al: Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience 1995;64:209-217.
13. Ohm TG, et al: Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol 1999;98:273-280.
14. Bigler ED, et al: Dementia, quantitative neuroimaging, and apolipoprotein E genotype. Am J Neuroradiol 2000;21:1857-1867.
15. Hashimoto M, et al: Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 2001;57:1461-1466.
16. Lehtovirta M, et al: Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 1995;67:65-72.
17. Mori E, et al: Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon 4 allele. Ann Neurol 2002;51:209-214.
18. Lemaitre H, et al: No epsilon 4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. Neuroimage 2005;24:1205-1213.
19. Yamaguchi S, et al: Temporal progression of hippocampal atrophy and apolipoprotein E gene in Alzheimer's disease. J Am Geriatr Soc 1996;44:216-217.
20. Fleisher A, et al: Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 2005;62:953-957.
21. Lind J, et al: Reduced hippocampal volume in non-demented carriers of the apolipoprotein E epsilon 4: relation to chronological age and recognition memory. Neurosci Lett 2006;396:23-27.
22. Soininen H, et al: Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E epsilon 4 allele. Neurology 1995;45:391-392.
23. Tohgi H, et al: Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E epsilon 4 allele. Neurosci Lett 1997;236:21-24.
24. Geroldi C, et al: Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study. J Neurol Neurosurg Psychiatry 2000;68:93-96.
25. Serra-Grabulosa JM, et al: Apolipoproteins E and C1 and brain morphology in memory impaired elders. Neurogenetics 2003;4:141-146.
26. Talbot C, et al: Protection against Alzheimer's disease with apoE ε2. Lancet 1994;343:1432-1433.
27. Kaur M, et al: APOE2 and consanguinity: a risky combination for Alzheimer's disease. J Alzheimers Dis 2005;8:293-297.
28. van Duijn CM, et al: The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol 1995;37:605-610.
29. den Heijer T, et al: Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology 2002;59:746-748.
30. Barboriak DP, et al: Hippocampal sulcal cavities on MRI: relationship to age and apolipoprotein E genotype. Neurology 2000;54:2150-2153.
31. Du AT, et al: Age effects on atrophy rates of entorhinal cortex and hippocampus. Neurobiol Aging 2006;27:733-740.
32. Geroldi C, et al: APOE-epsilon 4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999;53:1825-1832.
33. Juottonen K, et al: Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry 1998;65:322-327.
34. Barber R, et al: MRI volumetric study of dementia with Lewy bodies - A comparison with AD and vascular dementia. Neurology 2000;54:1304-1309.
35. Enzinger C, et al: Risk factors for progression of brain atrophy in aging - Six-year follow-up of normal subjects. Neurology 2005;64:1704-1711.
36. Yasuda M, et al: Apolipoprotein E epsilon 4 allele and whole brain atrophy in late-onset Alzheimer's disease. Am J Psychiatry 1998;155:779-784.
37. DeCarli C, et al: Impact of apolipoprotein E epsilon 4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke 1999;30:1548-1553.
38. Carmelli D, et al: The joint effect of apolipoprotein E epsilon 4 and MRI findings on lower-extremity function and decline in cognitive function. J Gerontol Seri A Biol Sci Med Sci 2000;55:M103-M109.
39. Boccardi M, et al: APOE and modulation of Alzheimer's and frontotemporal dementia. Neurosci Lett 2004;356:167-170.
40. Gunning-Dixon FM, et al: The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. Neuropsychology 2000;14:224-232.
41. Wahlund LO, et al: White matter hyperintensities in dementia: does it matter? Magn Reson Imaging 1994;12:387-394.
42. Hogh P, et al: Single photon emission computed tomography and apolipoprotein E in Alzheimer's disease: impact of the epsilon 4 allele on regional cerebral blood flow. J Geriatr Psychiatry Neurol 2001;14:42-51.
43. Lehtovirta M, et al: Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry 1998;64:742-746.
44. Lehtovirta M, et al: SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry 1996;60:644-649.
45. van Dyck CH, et al: Absence of an apolipoprotein E epsilon 4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease. Arch Neurol 1998;55:1460-1466.
46. Reiman EM, et al: From The cover: correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism. PNAS 2005;102:8299-8302.
47. Small GW, et al: Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942-947.
48. Reiman EM, et al: Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
49. Lee KU, et al: Influence of the apolipoprotein E type 4 allele on cerebral glucose metabolism in Alzheimer's disease patients. J Neuropsychiatry Clin Neurosci 2003;15:78-83.
50. Hirono N, et al: The effect of APOE epsilon 4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology 2002;58:743-750.
51. Greenwood PM, et al: Genetics and visual attention: selective deficits in healthy adult carriers of the epsilon 4 allele of the apolipoprotein E gene. Proc Natl Acad Sci USA 2000;97:11661-11666.
52. Greenwood PM, et al: Scaling of visuospatial attention undergoes differential longitudinal change as a function of APOE genotype prior to old age: results from the NIMH BIOCARD study. Neuropsychology 2005;19:830-840.
53. Dik MG, et al: Memory complaints and APOE-epsilon 4 accelerate cognitive decline in cognitively normal elderly. Neurology 2001;57:2217-2222.
54. van Dijk EJ, et al: Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004;55:570-575.
55. Skoog I, et al: Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions. Arch Neurol 1997;54:267-272.
56. Pesaresi M, et al: Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006;27:904-905.
57. Russo C, et al: Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. PNAS 1998;95:15598-15602.
58. Thompson PM, et al: Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 2003;23:994-1005.
59. Scarmeas N, et al: Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon 4 allele). Am J Geriatr Psychiatry 2004;12:596-605.
60. den Heijer T, et al: Alcohol intake in relation to brain magnetic resonance imaging findings in older persons without dementia. Am J Clin Nutr 2004;80:992-997.
61. Farlow MR, et al: Impact of APOE in mild cognitive impairment. Neurology 2004;63:1898-1901.
62. Wang PN, et al: The MCI study in Taiwan. Acta Neurol Taiwan 2006;15:66-68.
63. Reiman EM, et al: Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol 1998;44:288-291.
64. Schmidt H, et al: Apolipoprotein E ε4 allele in the normal elderly: neuropsychologic and brain MRI correlates. Clin Genet 1996;50:293-299.
65. Basso M, et al: Apolipoprotein E epsilon 4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiol Aging 2006;27:1416-1424.
66. Jack CR, et al: Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology 1998;51:993-999.
67. Jack CR, et al: Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol 1998;43:303-310.
68. Espeseth T, et al: Interactive effects of APOE and CHRNA4 on attention and white matter volume in healthy middle-aged and older adults. Cogn Affect Behav Neurosci 2006;6:31-43.
69. Pennanen C, et al: The effect of apolipoprotein polymorphism on brain in mild cognitive impairment: a voxel-based morphometric study. Dementia Geriatr Cogn Disord 2006;22:60-66.
70. Wishart HA, et al: Regional brain atrophy in cognitively intact adults with a single APOE epsilon 4 allele. Neurology 2006;67:1221-1224.
71. Tanaka S, et al: Inferior temporal lobe atrophy and APOE genotypes in Alzheimer's disease - X-ray computed tomography, magnetic resonance imaging and Xe-133 SPECT studies. Dementia Geriatr Cogn Disord 1998;9:90-98.
72. Wahlund LO, et al: Inheritance of the ApoE epsilon 4 allele increases the rate of brain atrophy in dementia patients. Dementia Geriatr Cogn Disord 1999;10:262-268.
73. Yoshida S, et al: Clinical features and alterations in the inferior horn sizes in lateral ventricle in Alzheimer's patients with different ApoE genotype in Japanese population. Progr Neuropsychopharmacol Biol Psychiatry 2001;25:1377-1384.
74. de Leeuw FE, et al: Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004;35:1057-1060.
75. Steffens DC, et al: Apolipoprotein E genotype and subcortical vascular lesions in older depressed patients and control subjects. Biol Psychiatry 2003;54:674-681.
76. Schmidt R, et al: Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage: results of the Austrian Stroke Prevention Study. Stroke 1997;28:951-956.
77. Bronge L, et al: White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype. Dementia Geriatr Cogn Disord 1999;10:89-96.
78. Amar K, et al: Are genetic factors important in the aetiology of leukoaraiosis? Results from a memory clinic population. Int J Geriatr Psychiatry 1998;13:585-590.
79. Barber R, et al: Apolipoprotein E epsilon 4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol 1999;56:961-965.
80. Bigler ED, et al: Dementia, asymmetry of temporal lobe structures, and apolipoprotein E genotype: relationships to cerebral atrophy and neuropsychological impairment. J Int Neuropsychol Soc 2002;8:925-933.
81. Bracco L, et al: Alzheimer's disease: role of size and location of white matter changes in determining cognitive deficits. Dementia Geriatr Cogn Disord 2005;20:358-366.
82. Doody RS, et al: Does APO epsilon 4 correlate with MRI changes in Alzheimer's disease? J Neurol Neurosurg Psychiatry 2000;69:668-671.
83. Gurol ME, et al: Plasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006;66:23-29.
84. Hirono N, et al: Effect of the apolipoprotein E epsilon 4 allele on white matter hyperintensities in dementia. Stroke 2000;31:1263-1268.
85. Borroni B, et al: Functional correlates of apolipoprotein E genotype in frontotemporal lobar degeneration. BMC Neurol 2006;6:31.
86. Sun ZW, et al: Decreased cerebral blood flow velocity in apolipoprotein E epsilon 4 allele carriers with mild cognitive impairment. Eur J Neurol 2007;14:150-155.
87. Drzezga A, et al: Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 2005;64:102-107.
88. Mosconi L, et al: Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve. J Neurol Neurosurg Psychiatry 2005;76:15-23.
89. Mosconi L, et al: MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332-2340.
90. Mosconi L, et al: Brain metabolic decreases related to the dose of the ApoE ε4 allele in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:370-376.
91. Mosconi L, et al: Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study. Psychiatry Res Neuroimag 2004;130:141-151.
92. Corder EH, et al: No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Arch Neurol 1997;54:273-277.
93. Hirono N, et al: Lack of association of apolipoprotein E epsilon 4 allele dose with cerebral glucose metabolism in Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:362-367.